Apimeds Pharmaceuticals US, Inc. Cash Flow Conversion Efficiency
Apimeds Pharmaceuticals US, Inc. cash flow conversion efficiency. Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has a cash flow conversion efficiency ratio of -0.017x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($126.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Apimeds Pharmaceuticals US, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Apimeds Pharmaceuticals US, Inc. (2021–2025)
Cash flow conversion efficiency of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Apimeds Pharmaceuticals US, Inc. for real-time trading data and today's change.
Apimeds Pharmaceuticals US, Inc. Cash Flow Conversion Ratio Explained
Apimeds Pharmaceuticals US, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Apimeds Pharmaceuticals US, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their cash flow conversion efficiency. Review how financially flexible is Apimeds Pharmaceuticals US, Inc. to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Comprehensive Healthcare Systems Inc
V:CHS
|
-0.033x |
|
BIRD RIVER RES. INC.
F:1Q1A
|
N/A |
|
Traws Pharma Inc
NASDAQ:TRAW
|
-4.438x |
|
Beowulf Mining PLC
ST:BEO-SDB
|
N/A |
|
Azucar Minerals Ltd
V:AMZ
|
-0.360x |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
0.015x |
|
LOBO EV TECHNOLOGIES LTD. Ordinary shares
NASDAQ:LOBO
|
-0.465x |
|
TANTALEX LITHIUM RES.CORP
F:DW8
|
0.067x |
Annual Cash Flow Conversion Efficiency for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. Also see how large is Apimeds Pharmaceuticals US, Inc.'s balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $153.35 Million | $-8.93 Million | -0.058x | -110.78% |
| 2024-12-31 | $-1.36 Million | $-733.53K | 0.540x | +102.74% |
| 2023-12-31 | $31.87K | $-627.79K | -19.698x | -3236.44% |
| 2022-12-31 | $-713.61K | $-448.17K | 0.628x | -81.80% |
| 2021-12-31 | $-238.48K | $-823.11K | 3.451x | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.